Aims To report contemporary regression rates from impaired glucose regulation to normal glucose tolerance, identify modifiable factors associated with early regression, and establish whether it affects subsequent diabetes risk in a population-based cohort.
Introduction
Impaired glucose regulation (IGR; also known as prediabetes or intermediate hyperglycaemia) increases the risk of Type 2 diabetes mellitus, can be identified using fasting glucose, 2-h glucose or HbA 1c levels, and has become increasingly prevalent over the last two decades. For example, in the USA, it is estimated that the prevalence of IGR [defined in that study as an HbA 1c level 39-46 mmol/mol (5.7-6.4%)] more than doubled from 5.8% in the period 1988-1994 to 12.4% in 2005-2010 [1] . In the UK, a recent study found that approximately one in three adults have IGR (defined by the same HbA 1c criteria) from which more than one million incident Type 2 diabetes cases are predicted annually [2] . Appropriately targeted, effective primary prevention strategies are therefore needed. Randomized controlled trials have shown that dietary change, physical activity and pharmacotherapy can delay or prevent progression from IGR [3] [4] [5] . Real-world replication of these results is challenging, with 'pragmatic' programmes of lifestyle interventions typically achieving 2-3% weight loss after 1 year, compared with 9-10% in randomized controlled trials [6] . Identifying individuals achieving early normal glucose tolerance (NGT) may improve the efficiency of prevention programmes by allowing them to concentrate on those at greatest Type 2 diabetes risk.
Approximately half of those with IGR may revert to NGT as a result of measurement variability or lifestyle change after identification [7, 8] , but this conclusion is based on studies that are at least 20 years old or are concentrated on progression to diabetes rather than regression to NGT [9] [10] [11] [12] [13] [14] . It is unclear whether regression rates have changed over time, or whether regression to NGT is associated with lower diabetes risk outside of the Diabetes Prevention Programme, which included a highly structured intervention [15, 16] . Furthermore, we were interested in identifying modifiable factors for regression to NGT, because many healthcare organizations now routinely screen for IGR, resulting in an incredibly high number of IGR diagnoses, thus public health approaches for preventing Type 2 diabetes in these people are urgently needed.
We aimed to report regression rates from IGR to NGT, establish whether early regression affects cumulative diabetes incidence, and identify modifiable factors associated with achieving regression using a well-characterized, non-intervention cohort in a clinically relevant, contemporary population.
Patients and methods

Definitions of normal glucose tolerance, impaired glucose regulation and Type 2 diabetes
A 75-g oral glucose tolerance test (OGTT) was used to diagnose NGT and IGR. Type 2 diabetes was diagnosed using a 75-g OGTT or by the participant's own physician. NGT was defined as fasting glucose < 6.1 mmol/l and 2-h glucose < 7.8 mmol/l, IGR as impaired fasting glucose (IFG; fasting glucose 6.1-6.9 mmol/l) and/or impaired glucose tolerance (IGT; 2-h glucose 7.8-11.0 mmol/l), and Type 2 diabetes as fasting glucose ≥ 7.0 mmol/l and/or 2-h glucose ≥ 11.1 mmol/l.
Study population
The ADDITION-Prediabetes Cohort Study is an observational follow-up of participants with IGR at baseline in ADDITION-Leicester (NCT00318032), which is described in detail elsewhere [17, 18] . Briefly, people from 20 representative general practices in Leicestershire and Rutland, UK were invited for diabetes screening if they were aged 40-75 years (25-75 years for South Asians) inclusive. Exclusion criteria were pre-existing diabetes, terminal illness or pregnancy. Participants were screened with a 75-g OGTT, and WHO 1999 diagnostic criteria were applied [19] . Participants with IFG and/or IGT at baseline (2004) (2005) (2006) (2007) were invited to join the ADDITION-Prediabetes cohort (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . They received rudimentary lifestyle advice consistent with standard practice at the time, and were invited to annual re-screens identical to the baseline assessment, for a total of five visits. If diabetes was diagnosed during a followup visit, a second 75-g OGTT was performed within 1 week and if the Type 2 diabetes diagnosis was confirmed then the participant was referred to their own physician and they exited the study. If the second test was not in the diabetes range, the participant continued in the study. A physician diagnosis of diabetes at any time during follow-up was also considered an endpoint. If, at follow-up, the participant was diagnosed with NGT or IGR (IFG and/or IGT) they continued in the study. The study received ethical approval from the University Hospitals of Leicester (UHL09320) and Leicestershire Primary Care Research Alliance (64/2004) local research ethics committees and was conducted in accordance with the Helsinki Declaration. All participants gave written informed consent.
Variables
At each visit, participants provided information on demographics, smoking status, alcohol consumption, previous medical history and family history of disease. HbA 1c and anthropometric measurements were recorded by trained staff according to standard operating procedures. Height was measured to the nearest 0.1 cm using a rigid stadiometer and weight was measured in light indoor clothing to the nearest 0.1 kg with a Tanita scale (Tanita, Amsterdam, the Netherlands). BMI (kg/m 2 ) was used to create the categories normal 2 ). Waist circumference was measured at the mid-point between the lower costal margin and the level of the anterior superior iliac crest to the nearest 0.1 cm. Socioeconomic status was measured using Index of Multiple Deprivation scores, which are a postcode-based measure of socio-economic status; higher scores indicate higher deprivation. Physical activity was self-reported using a validated 7-day questionnaire (the IPAQ) [20] . The total metabolic equivalents of task (METS) per week were estimated by summing the walking, moderate and vigorous METS.
Statistical analysis
Baseline characteristics were summarized as mean (SD) for continuous variables and count (percentage) for categorical
What's new?
• We provide contemporary estimates of the natural history of impaired glucose regulation, which are vital for service planning.
• Reductions in weight and waist circumference were associated with regression to normal glucose tolerance, which was in turn associated with a much lower subsequent risk of Type 2 diabetes.
• These data are from a population-based UK cohort and so are more generalizable than existing data from randomized controlled trials.
• A message for patients identified with intermediate hyperglycaemia could be that if they lose any weight in the year after diagnosis then they may be almost twice as likely to achieve normal glucose tolerance. 
Results
Participants
Of the 6749 participants screened in ADDITION-Leicester, 1080 had IGR and were invited to join the ADDITIONPrediabetes cohort (Fig. 1) ; a total of 910 participants (84.3%) joined. The age (P = 0.422) and ethnicity (P = 0.287) distribution were similar among those who did and did not join, but women were more likely to join than men (P = 0.038). Participants were excluded because they did not attend the first follow-up (91; 10.0%) or their glycaemic status at 1 year was unknown (2; 0.2%); therefore, 817 (89.8%) participants were analysed [mean (range) time to 1-year follow-up = 1.2 (0.5-1.5) years]. The participants' mean (SD) age was 60 (10) years (Table 1 ). There were approximately equal numbers of men (47%) and women (53%), a quarter of participants were non-white, and only 14% were in the normal BMI category. At baseline, 18% of participants had IFG, 68% had IGT, and 14% had both IFG and IGT. Those who regressed to NGT were slightly younger at baseline than those who did not (P = 0.07; Table 1 ), had lower fasting glucose (P < 0.001), 2-h glucose (P < 0.001), HbA 1c (P < 0.001), waist circumference (P < 0.001), and weight (P < 0.01) at baseline on average, and were less likely to be obese (P < 0.01). Among those who did not regress to NGT, 22% had both IFG and IGT compared with only 7% of those who did regress (P < 0.001).
After adjustment, participants who had lost 0.1-3% (3% was the median weight loss among those who lost weight) of their baseline weight by 1 year (18.6%) were significantly more likely to regress to NGT than those who maintained their baseline weight or gained weight [adjusted odds ratio (OR) 1.81, 95% CI 1.08, 3.03; Table 2 ]. Those who lost > 3% of their baseline weight were also more likely to regress to NGT compared with those who maintained or gained weight, but this was not significant (adjusted OR 1.30, 95% CI 0.81, 2.09). There was also a non-significant benefit in losing 0.1-3 cm (the median observed reduction among those in whom waist circumference decreased) of baseline waist circumference (adjusted OR 1.15; 95% CI 0.65, 2.02) and a greater, significant benefit in losing > 3 cm of baseline waist circumference (adjusted OR 1.78, 95% CI 1.03, 3.06). Regressing to NGT was not significantly associated with change in physical activity, alcohol consumption or statin treatment (P > 0.05 for all). There were too few smokers at baseline (n = 58) to allow a meaningful analysis of smoking cessation, and diet was not measured. The 770 participants without diabetes at 1 year remained eligible for annual re-screening; 630 (81.1%) attended at least one additional follow-up visit, and were included in the remaining analyses. There were no significant differences between the baseline characteristics of those who did (n = 630) and did not (n = 140) return for further followup, except that women with IGR at 1 year were more likely to withdraw than men, and people with NGT at 1 year who withdrew had a higher baseline weight than those who did not (Table S1 ). After the 1-year follow-up, the mean (range) further follow-up was 2.8 (0.0-4.4) years. A median of three further follow-up visits were attended (i.e. four follow-up visits in total). During this time, 81 incident Type 2 diabetes cases were diagnosed (72 at a study visit; nine by their own physician) over 1752 person-years [incidence rate 46.3 (95% CI 37.3, 57.6)] per 1000 person-years.
People with NGT at 1 year were more likely to subsequently remain diabetes-free than those with IGR at 1 year (Fig. 2) . This reflects the Type 2 diabetes incidence rates of 90.0 (95% CI 70.0, 115.7) and 18.7 (95% CI 12.1, 29.0) per 1000 person-years for those who did not and did regress to NGT at 1 year, respectively. The unadjusted hazard ratio for Type 2 diabetes was 0.20 (95% CI 0.12, 0.33) for regression to NGT compared with not regressing, which was largely unchanged in adjusted models (Table 3 ). In sensitivity analyses that included HbA 1c in Type 2 diabetes diagnosis, the association between regression to NGT and future Type 2 diabetes risk was attenuated, but regression still had a strong, highly significant protective effect (Table S2) .
Discussion
In this contemporary population, 54% of those with IGR regressed to NGT at 1 year without a highly structured, formal intervention. This is similar to historical cohorts suggesting that the natural history of IGR has remained fairly stable over time [7] [8] [9] [10] [11] [12] [13] [14] . Notably, the percentage of participants with both IFG and IGT at baseline was much higher among those who did not regress at 1 year compared with those who did regress. This confirms previous findings indicative of an incremental relationship between glucose concentration and diabetes risk below the Type 2 diabetes diagnostic threshold. This implies that classifications encapsulating IFG and IGT have a greater degree of b-cell dysfunction and more advanced pathophysiology. The individuals who regressed from IGR to NGT within 1 year developed 71 fewer Type 2 diabetes cases per 1000 person- years in subsequent follow-up than those who did not regress. Our estimated progression rate from IGR to Type 2 diabetes of 46 cases per 1000 person-years is consistent with previous studies [22] . To our knowledge, we are the first to investigate changes that an individual with IGR can make to improve their chance of regressing to NGT. In addition to regression being associated with reduced diabetes incidence, dysglycaemia is associated with adverse outcomes even below the diabetes thresholds [23] providing further motivation for attempting to regress to NGT, rather than remaining in an IGR state.
The most important factor appeared to be decreases in body size, with higher regression rates among those who lost any weight in the year after diagnosis compared with those who did not, although we found no evidence of a dose-response relationship. Weight loss of 0. IFG, impaired fasting glucose; IGT, impaired glucose tolerance; METS, metabolic equivalent of task; NGT, normal glucose tolerance.
ª 2016 Diabetes UK decrease of ≥ 3 cm were associated with ORs of almost 2, which are similar to or greater than the pooled ORs of regression associated with various antidiabetic medications reported in a recent meta-analysis [5] . This finding that a small magnitude of weight loss was associated with regression to NGT is consistent with the findings of the Diabetes Prevention Program, which found that there was a strong relationship between weight loss and subsequent incident Type 2 diabetes among people at high risk of Type 2 diabetes [24] . This raises questions about how this degree of body size reduction can be achieved. Physician referral to a commercial weight loss programme can result in a 1-year mean weight loss of~8% [25] . A multitude of weight loss clinical trial data suggest that 5-9% weight loss can be achieved through real-world reduced-energy diets and exercise, with some additional benefit of weight loss medications [26] . In the present study, participants received minimal intervention, namely, a leaflet promoting the benefits of a healthy lifestyle. This, combined with the knowledge that they were at higher risk of developing Type 2 diabetes, appears to have encouraged weight loss in some participants, with 3% being the median weight loss observed at 1 year among those who lost weight, although regression to the mean could also explain this. This suggests that this moderate weight loss is achievable and is a realistic goal to set in a clinical setting, although it is slightly lower than that currently recommended in some guidelines [27] . Furthermore, this level of weight loss can be achieved when diabetes prevention interventions are implemented in a pragmatic manner [6] . Changes in physical activity, alcohol consumption and statin use were not associated with regressing to NGT. This might be because these variables were assessed by imprecise self-report measures that may be subject to social desirability bias [28] , or may not be sensitive to change at the individual level [29] . Associations were generally in the expected direction but small, therefore, the study may not have been sufficiently powered to detect changes in these variables. Further investigation is required before conclusions can be drawn regarding the effect of these variables on regression to NGT.
Unsurprisingly, BMI, waist circumference and glucose indices were higher at baseline in the non-regression (sustained IGR or developed Type 2 diabetes) group, indicating that fat mass-driven insulin resistance and glucose concentration are predictors of diabetes in the present study population. In the Diabetes Prevention Program Outcomes Study, both regression and IGR groups were well matched for BMI and treatment method, suggesting improved b-cell function may relate directly to observed glucose-lowering [16] . In the present study, NGT remained an independent determinant of incident diabetes in a multivariate model, adjusting for BMI, family history of diabetes, physical activity and other factors. Aggressive initial management of glucose has been associated with a recovery effect on subsequent b-cell function, which may be sufficient to influence treatment course in newly diagnosed modest hyperglycaemia [30, 31] .
This study has notable strengths, such as the inclusion of a multi-ethnic cohort based on the WHO definition of intermediate hyperglycaemia and with only 75-g OGTT data included in our definition of IGR, which, it has been argued, is a preferable approach [32] . Furthermore, we included HbA 1c in the definition of Type 2 diabetes as a sensitivity analysis, in line with current WHO recommendations [21] , and this did not change our conclusions. This was an observational cohort study recruited from a community population, so the results were not attributable to a particular treatment regime, and are more generalizable than data from highly selected populations in randomized controlled trials. These data convey an important public health message that people who achieve modest weight loss within 1 year of IGR diagnosis are approximately twice as likely to regress to a metabolic state associated with a significantly lower risk of diabetes and cardiovascular disease. Given the high prevalence of IGR, it is important to emphasize the effectiveness of lifestyle modification in this condition; our observations provide new information that will reinforce informed decision-making and target-driven change in this regard. As screening for Type 2 diabetes is now widespread and endorsed by many health authorities, increased identification of accepted IGR ranges is inevitable, which is as an opportunity to reach high-risk cases with undisputedly effective interventions.
Limitations of the present study should be considered when interpreting its findings. First, participant loss to follow-up, particularly towards the end of the study, could have introduced ascertainment bias. Whilst acknowledging this as a potential source of error, non-attendee characteristics were nearly identical to those individuals completing the study and there was no evidence that reverting to NGT at 1 year influenced the subsequent return rate. Second, this study was not designed to explore the pathophysiological basis of any relationship between early glucose-lowering and incident diabetes. A second baseline 75-g OGTT may have reclassified some borderline cases of IGR, and it could be argued that these individuals actually have NGT [33] . Whilst acknowledging a lack of confirmatory testing for nondiabetes range glucose dysregulation as a limitation of the present study, sensitivity analyses excluding participants close to diagnostic thresholds for NGT at baseline did not substantially change the results, except that some results were no longer significant (Tables S3 and S4 ). It therefore seems unlikely that we are simply observing baseline variability in the 75-g OGTTs of individuals with lower rates of progression to diabetes. Presumably, if variability in glucose testing was the sole reason for regression then we would not expect to see such a strong link with Type 2 diabetes outcomes as that observed in the present study. Third, this observational work does not infer causality. Relationships between body mass change and regression to NGT could have occurred by chance and can only be definitely tested in controlled intervention studies. Trial data do exist for weight loss and regression to NGT from the Diabetes Prevention Program, which also suggests that such regression conveys additional cardiovascular benefits because any degree of dysglycaemia can have adverse effects [15, 16] . Whilst these data provide evidence of a causal association, to our knowledge there are no such data in other settings and populations. Finally, the study may have been underpowered to detect some associations but because of the large effect sizes many of these were highly statistically significant and there was almost no bias in those lost to follow-up. Measurement of some of the modifiable risk factors could have been improved upon.
We have confirmed that early regression from intermediate hyperglycaemia to NGT is associated with reduced diabetes incidence, and extended these results into a non-intervention setting that has greater generalizability than previous studies. Our findings provide new evidence that reductions in body size may be the most important factor for increasing the chance of regression to NGT. A simple message for those identified with intermediate hyperglycaemia or prediabetes could be that if they achieve any degree of weight loss within 1 year then they are twice as likely to achieve NGT. Finally, rates of progression and regression appear similar to those in other historical data and should provide important contemporary information for healthcare planners involved in diabetes prevention.
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